HDAC9 and cancer: Several preclinical studies have demonstrated suppression of cancer growth with genetic knockdown or pharmacologic inhibition of PAX8 (32, 33), including histone deacetylases (HDAC) inhibitors, which may epigenetically downregulate PAX8 transcripts and are a class of small molecule drugs now approved for cancer therapy (34).